FDA Approves Three-Antigen Hepatitis B Vaccine

The FDA approved a new hepatitis B vaccine [recombinant]) (PreHevbrio) for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults 18 years of age and older: small (S), middle (pre-S2), and large (pre-S1) hepatitis B surface antigens. It is the only three-antigen hepatitis B vaccine to be approved in the United States. PreHevbrio is a product of VBI Vaccines.

The FDA’s approval was based on data from two phase 3 studies that compared the safety and immunogenicity of the vaccine candidate to Engerix-B, a single-antigen HBV vaccine, in adults 18 years of age and older. PreHevbrio was shown to be noninferior, with a seroprotection rate (SPR) of 91.4% versus 76.5% for Engerix-B. Among study subjects 45 years of age and over, SPR was 89.4% with PreHevbrio, versus 73.1% with Engerix-B. In the second trial, PreHevbrio demonstrated noninferiority, with an SPR of 99.3% after the three-dose series, compared with 94.8% for Engerix-B.

The most common local reactions reported in the trials were injection-site pain and tenderness; systemic reactions included headache, fatigue, and myalgia. Consult product labeling for full prescribing information.

Join our email list

Get new course alerts, newsletters and more delivered directly to your inbox

By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.